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Abstract
Background: Cancer cells recurrently develop into acquired resistance to the administered drugs. The iatrogenic 
mechanisms of induced chemotherapy-resistance remain elusive and the degree of drug resistance did not exclusively 
correlate with reductions of drug accumulation, suggesting that drug resistance may involve additional mechanisms. 
Our aim is to define the potential targets, that makes drug-sensitive MCF-7 breast cancer cells turn to drug-resistant, for 
the anti-cancer drug development against drug resistant breast cancer cells.
Methods: Doxorubicin resistant human breast MCF-7 clones were generated. The doxorubicin-induced cell fusion 
events were examined. Heterokaryons were identified and sorted by FACS. In the development of doxorubicin 
resistance, cell-fusion associated genes, from the previous results of microarray, were verified using dot blot array and 
quantitative RT-PCR. The doxorubicin-induced expression patterns of pro-survival and pro-apoptotic genes were 
validated.
Results: YB-1 and ABCB5 were up regulated in the doxorubicin treated MCF-7 cells that resulted in certain degree of 
genomic instability that accompanied by the drug resistance phenotype. Cell fusion increased diversity within the cell 
population and doxorubicin resistant MCF-7 cells emerged probably through clonal selection. Most of the drug 
resistant hybrid cells were anchorage independent. But some of the anchorage dependent MCF-7 cells exhibited 
several unique morphological appearances suggesting minor population of the fused cells maybe de-differentiated 
and have progenitor cell like characteristics.
Conclusion: Our work provides valuable insight into the drug induced cell fusion event and outcome, and suggests 
YB-1, GST, ABCB5 and ERK3 could be potential targets for the anti-cancer drug development against drug resistant 
breast cancer cells. Especially, the ERK-3 serine/threonine kinase is specifically up-regulated in the resistant cells and 
known to be susceptible to synthetic antagonists.
Background
The prognosis of breast cancer patients is closely associ-
ated with the response of the tumor cells to chemother-
apy. Doxorubicin is one of the primary chemotherapeutic
agents used for the treatment of breast cancer [1,2]. Vari-
ous tumors initially respond to administered drugs, how-
ever, once the cancer cells could gain resistance during
anticancer drug treatment, there are only a few treatment
options [3,4]. Resistance to chemotherapy is believed to
cause treatment failure in over 90% of the patients with
metastatic cancer [5,6]. Multidrug resistant cancer cells
are thought to be derived from emerging clones within
primary tumors [7] and all multidrug resistances were
found to be closely related with additional changes to the
already altered copy number profile of the breast tumors
[8,9]. Up to now, the iatrogenic mechanisms of induced
chemotherapy-resistance and the question of whether
cells with drug resistance potential are frequent or atypi-
cal within human cancers remain mainly elusive.
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Page 2 of 10Interestingly, cancer cells were known to fuse with
many cell types in vivo, including stromal cells and
endothelial cells [10,11]. Cell fusion was reported to
account for the plasticity of adult stem cells in vivo [12],
while an accidental heterotypic cell fusion was noted to
build tetraploid cells that may lead to initiation and pro-
gression of neoplastic tumor through genomic instability
[13]. However, the mechanism of action of doxorubicin
appears to be complex and unclear, moreover, doxorubi-
cin was known to interact directly with tumor cell mem-
brane proteins.
Recently, Y-box binding protein-1 (YB-1) was reported
as a stronger predictor, of all breast tumor subtypes spe-
cific survival, than estrogen receptor or HER-2 [14]. The
locus of YB-1 gene is on 1p34 and 80% of primary breast
tumors show increased copy numbers of chromosome 1
[15]. When cells are under the cytotoxic stimuli of anti-
cancer drugs, the stress-responsive protein YB-1 is
known to be translocated to the nuclei [16], YB-1 func-
tions as a transcription factor for the expression of the
well known membrane efflux pump, the multiple drug
resistance gene I (MDR1/ABCB1) that allows anti-cancer
drug resistance [17].
Recently, however, the resistance mechanisms are
revealed as multifactorial and no single protein expres-
sion is solely responsible for acquired multiple drug resis-
tance [18-21]. Amino acid sequence of p-Glycoprotein
ABCB5 was reported highly homologous to both of the
known human P-gp isoforms ABCB1 (MDR1) and
ABCB4 (MDR3), and new evidence has suggested that
ABCB5 could mediate cell to cell fusion [22]. On the basis
of this rationale and with our preliminary results from
microarray analysis on cell fusion (data not shown), we
postulated that cell fusion could be an essential prerequi-
site event prior to diversified MCF-7 subpopulations
emerging.
Therefore, the goals of the present study were, firstly, to
investigate whether the overexpression of YB-1 could
induce cell fusion on doxorubicin treatment, secondly, to
scrutinize whether this cell fusion event could increase
genetically diversified cell population, and finally, to
define the potential targets of pro-survival gene products
and pro-apoptotic ones (that makes drug-sensitive MCF-
7 breast cancer cells turn to drug-resistance).
Methods
Cell culture and drug selection
Human breast MCF-7 carcinoma cells were grown in
Dulbecco's modified Eagle's medium (GIBCO) supple-
mented with 10% (v/v) fetal bovine serum, 1% penicillin/
streptomycin (Gibco) in standard culture conditions (95%
air-5% CO2, 37°C). The cells were inspected on a daily
basis with inverted microscope and documented with
digital camera (Leica, DM IRB/DC300). 100 μl MCF-7
cells (2 × 104 cells/ml) were distributed into each well of
96 well plates (Becton Dickinson, USA) and allowed to
adhere 18 hours and further incubated for two weeks
with increasing concentrations (0.01--1000 nM) of doxo-
rubicin hydrochloride (Duchefa), to a final volume of 200
μl per well, then MTS reagent (The CellTiter 96® AQueous
Non-Radioactive Cell Proliferation Assay kit, Promega)
was added into each well and incubated for 2 h before
reading at a wavelength of 490 nm. A 50% growth inhibi-
tion (IC50) values for doxorubicin were calculated from
dose-response curves obtained from the three indepen-
dent experiments (Figure 1A and 1C). We generated dox-
orubicin resistant MCF-7 cell clones following the single-
step selection procedure with the optimized low dose-
effect of doxorubicin (10-20 nM). Then, the resistant
clones were maintained in the medium with or without
doxorubicin. The resistant phenotype of isolated clones,
after the single-step selection, was re-examined 24 weeks
later and confirmed to be stable. Time dependent effect
of doxorubicin, on cellular growth rate of MCF-7 cells,
was examined by incubating ~1000 cells with 10 nM dox-
orubicin for 15 days (with 3 day intervals) and the ratios
of viable cell percent were calculated by comparing the
Figure 1 Effect of different concentration of doxorubicin treat-
ments on the survival of MCF-7 breast cancer cell lines. A and C: Vi-
ability of MCF-7 cells in the presence of a series of concentrations of 
doxorubicin (0.01-1000 nM) for two weeks, the percent viability was 
measured following the standard protocols (non-radioactive cell pro-
liferation assay kit, Promega). B: Control MCF-7 cells; black circlet (d), 
doxorubicin-treated cells; white circlet (s). Time dependence effect 
response of doxorubicin (10 nM) on cellular growth rate of MCF-7 cells 
was assayed by comparing the each value with control. For the count-
ing of colony number, cells were stained with 1% methylene blue for 
20 m and washed with water. Each data point is the average of at least 
three independent experiments performed.
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cells were collected by centrifugation, then resuspended
in PBS buffer. The cell suspension was mixed with an
equal volume of trypan blue solution (0.4%). Each sample
was counted in triplicates with hemacytometer. Stained
(dead) and unstained (viable) cells were counted with an
inverted microscope.
Creation of GFP-YB-1 and DsRed-YB-1 expressing MCF-7 
cell lines
The human YB-1 coding sequence (containing 1.4 kb YB-
1) was amplified from pCMV-SPORT6/YB-1 (a generous
gift from Yun-Sik Yang, Genome Research Center for
Immune Disorders, Wonkwang University) and inserted
into EcoRV /Xho1 of multiple cloning site (MCS) of a
pcDNA3-EGFP vector (6.2 kb) and into EcoR1 and Apa1
of a pDsRed2-N1 vector (4.7 kb, BD Clontech). The vec-
tors, pcDNA3-EGFP/YB-1 and pDsRed2-N1/YB-1 (hav-
ing the initiator ATG codon of YB-1), direct expressions
of fusion proteins, GFP-YB-1 and DsRed-YB-1, respec-
tively under CMV promoter in MCF-7 cells. For that pur-
pose, 1 × 105 MCF-7 cells were grown on a 6-well plate
for 24 h and the expression constructs were transfected
into doxorubicin sensitive MCF-7 cells according to the
manufacturer's instructions (FuGENE 6, Roche). 48 h
after transfection, G418 (500 μg/ml, Duchefa) was added
for the selection of the stably transfected cells and contin-
ued for 2 weeks. The efficiency of the transfection was
evaluated 22 hours after transfection by observing the
green GFP and red DsRed fluorescence in the transfected
cells using an Axiovert 200 fluorescent microscope
(Zeiss), the images captured using a digital camera (Axio-
Cam MRm) and visualized and documented using the
AxioVision Rel 4.6 software.
Dot blot array assay analysis
Based on the knowledge gained from the microarray
assay (data not shown) on cell fusion, custom made dot
blot arrays were employed to verify whether the up-regu-
lated genes on fused cell hybrids are biologically relevant
in the development of doxorubicin resistance. The meth-
ods of array assay were adopted from the Atlas Select
Human Tumor Array (Clontech, PT1117-1, PT3399-1)
with modifications. The gene specific primers were
designed with MacVector software (International Bio-
technologies) employing a sequence data base. The prim-
ers were as follows: YB-1 forward, 5'-tcgcagtgtagg
agatggagagact-3'; YB-1 reverse, 5'-cggtaccgacgttgaggtg-
gct-3'; c-Kit forward, 5'-ggcgcgagggaggggaggcgagga-3'; c-
Kit reverse, 5'-aagtgcagcgagcgcggcaaagcc-3'; MAPT for-
ward, 5'-cccaacactcctcagaacgaacttatcc-3'; MAPT reverse,
5'-gccatcctggttcaaagttca-3'; GST forward, 5'-ttggccat-
gacgcgggttgt-3'; GST reverse, 5'-agttgggcacagaaacaaatctt-
gga-3'; GM-CSF2RA forward, 5'-agatctgacagcctgaacc
ctcct-3'; GM-CSF2RA reverse, 5'-gtgtcgcggaggcggagatg-
3'; 15-LOX-1 forward, 5'-ggctcgggaccaggtttgcc-3'; 15-
LOX-1 reverse, 5'-gtggcttgggtgatgggggc-3'; CypB forward,
5'-gagggcatggaggtggtgcg-3'; CypB reverse, 5'-gccagtg-
cagctcagagccc-3'; LCN2 forward, 5'-tcccagccccacctct-
gagc-3'; LCN2 reverse, 5'-atggtgttcgggctggtgcg-3'; GRP78
forward, 5'-aagcgccgcggcctgtattt-3'; GRP78 reverse, 5'-
acgccgacgcaggagtaggt-3'; RSK1 forward, 5'-cgtccactgg-
gaccaactgcc-3'; RSK1 reverse, 5'-agcagcagcaggaacagcagc-
3'; COX2 forward, 5'-ccaggcgacctgcgactcct-3'; COX2
reverse, 5'- accgtagtatacccccggtcgtg-3'; CRABP2 forward,
5'-tgctcaaagtgctgggggtga-3'; CRABP2 reverse; 5'-gcgcacg-
gtggtggaggttt-3'; Gapdh forward, 5'-ccaaacgggtcatcatctc-
3'; Gapdh reverse, 5'-tggatgcagggatgatgtt-3'; β-actin for-
ward, 5'-cctggcacccagcacaat-3' and β-actin reverse, 5'-
gccgatccacacggagtact-3'. For the cDNA amplification of
target genes, template was generated from polyA+-RNA
or genomic DNA of MCF-7 cells that were serially diluted
to give an optimal concentration for PCR. The subse-
quent PCR products were evaluated by gel electrophore-
sis on 1~2% agarose gels and confirmed a single PCR
product of the predicted size. Each 100 pmol of 14 cDNA
products were spotted onto nylon membranes (Hybond-
N+, Amersham) with QArray systems (Genetix) in dupli-
cates to eliminate potential non-specific single spot
hybridization. On the other hand, total RNA was recov-
ered with TRIzol reagent (Invitrogen) followed by isopro-
panol precipitation and ethanol washing from the each of
doxorubicin sensitive MCF-7 cells (5 × 106), after 0, 2, 4,
6, 12, 24 and 48 h of incubation with 20 nM doxorubicin.
Second purification was done by RNeasy Protect Mini kit
(Qiagen), following the manufacturer's protocol. For
cDNA labeling, total RNA was converted into α-32P-
labeled first strand cDNA with gene-specific primer
cocktails. After hybridization, the membrane was quickly
washed, then exposed to a phosphor imaging plate
(Molecular Dynamics) for three to five days. ImageQuant
version 1.2 (Molecular Dynamics) was used for visualiza-
tion and spot finding, spot quantification. The house
keeping genes (Actin, GAPDH) were employed for nor-
malization. For background subtraction and normaliza-
tion, the Excel (Microsoft) program was used. Spots
below threshold intensity were eliminated and the
expression ratio data were median-centered.
Microarray Assays
Total RNA (150 μg) was extracted from each of the non-
fused and fused MCF-7 cells (R2, FACS sorted) and
assayed with a Human Sentrix-6 V3 BeadChip that con-
taining 48,803 human genes (Illumina, GenoCheck,
Korea).
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In order to analyse the cell to cell fusion of the stably
strasfected cells (with pcDNA3-EGFP/YB-1 and
pDsRed2-N1/YB-1), the two transfectants were mixed (1
to 1 ratio) and co-cultured with or without 10 nmol/L
doxorubicin for 6 days and 1 × 107/ml cells were resus-
pended in (1×) PBS for immediate analysis or in (1×) PBS
containing 5% FBS for cell sorting. Fluorescence was
detected using a MoFlow flow cytometer/cell sorter
(Beckman Coulter) and analyzed using Summit 5.1 soft-
ware. Dead cells were gated out first and hetertypically
fused cells gated and sorted based on merged fluores-
cence of GFP and DsRed.
Western blot analysis
The same numbers of MCF-7 cells (5 × 107) were lysed
using 150 μl RIPA buffer with freshly added protease
inhibitors, then transferred to an Eppendorf microcentri-
fuge tube and mixed by inversion for 30 m at 4°C and cen-
trifuged at 14000 rpm for 30 m. The supernatant was
transferred to a new Eppendorf tube, the protein concen-
tration was determined by the Bradford method. The
protein extracts were electrophoresed by 12% SDS-
PAGE, then electrically transferred onto nitrocellulose
filters and probed with the following primary antibodies
(specific to the proteins that may associated with
acquired drug resistance): YB-1 (dilution factor 1:200,
Cell Signalling), c-Kit (1:1000, Cell Signalling); ERK1/2 (1:
1000, Cell Signalling); ERK3 (1: 500, Novus Biologicals);
FAS (1: 500, Santa Cruz Biotechnology); MAPT (1: 1500,
Proteintech Group); and MDR1 (1: 500, Santa Cruz Bio-
technology), ABCB5 (1: 2000, ProSci); PARP-1 (1: 2000,
Trevigen); β-Actin (1:5000, Sigma) was used as a loading
control. The membranes were rinsed with Tris-buffered
saline, treated with horseradish peroxidase-conjugated
secondary antibody (Jackson ImmunoResearch Labora-
tories) was applied for 1 h at 1:2000 dilution. After four
washes in PBST, blots were treated with ECL-plus (Amer-
sham Pharmacia) according to the manufacture's specifi-
cation, and exposed to Biomax ML film (Kodak) to detect
the protein bands. The intensity of the band derived from
each sample was measured by AlphaImager® HP densi-
tometer.
Results
Increased genomic instability of MCF-7 cells during single-
step low dose doxorubicin selection
Figure 1A and 1C shows percentage vitality of MCF-7
cells. The dose-effect of doxorubicin (0.01, 0.1, 1, 10 and
1000 nM) on cellular growth rate of MCF-7 was observed
over the period of two weeks. Our proximal 50% growth
inhibition (IC50) of doxorubicin for parental MCF-7 cells
was 68 nM and for one of the pre-selected doxorubicin
resistant clones was 120 nM. 10-20 nM doxorubicin was
employed based on the previously known reports [23,24].
To examine the time-dependent effect of doxorubicin on
cell proliferation, ~1000 cells were then incubated with
10 nM doxorubicin for 15 days, and further extended up
to 8 weeks. Compared to the doxorubicin-non treated
cells, the death rate of doxorubicin-treated cells was grad-
ually reduced up to day 9, and eventually the cell growth
rate exceeded the control at day 12 (Figure 1B). However,
an abnormally high proliferation was not observed that
accounts for a typical aggressive tumor mass. The idea
behind the clonal evolution model is that neoplasms con-
tinue to divide and fail to die until they are well adapted.
Therefore, a shorter doubling time would not necessarily
confer an additional survival advantage, especially in the
development of acquiring drug resistance. The ratio of
MCF-7 cells with the multiple nuclei is significantly
increased, before doxorubicin-resistant MCF-7 clones
emerged, compared to the drug sensitive control MCF-7
cells. This indicates that certain degree of genomic insta-
bility is accompanied by the drug resistance phenotype
after a single low dose exposure to cancer cells over the
certain period of time. The doxorubicin-induced cell
fusion events were further examined using two MCF-7
transfectants having pcDNA3-EGFP/YB-1 or pDsRed2-
N1/YB-1.
Doxorubicin-induced homotypic and heterotypic cell 
fusion
Two MCF-7 transfectants (transfected either with
pcDNA3-EGFP/YB-1 or with pDsRed2-N1/YB-1, Figure
2) were co-cultured (1 to 1 ratio) with or without 10 nM
doxorubicin for 6 days and visualized by phase contrast
and fluorescence microscopy (Figure 2). In accordance
with previous studies [25], YB-1 was expressed almost
evenly in cytosol of MCF-7/YB-1 transfectants when
there was no drug-related stress (Figure 2A). However,
YB-1 localized mostly to the nucleus (Figures 2B and 2C)
in the doxorubicin treated cells. After doxorubicin treat-
ment, some cells maybe underwent homotypic cell
fusion, resulting in binucleated (DsRed stained) cells in
one cytosolic body (Figure 2E) and others further went
through nuclear fusion (Figures 2D, E and 2F). However,
we cannot exclude that some of these homotypic multi-
nucleated cells may also associate with mitotic defects or
with cytokinesis failure. Interestingly, the control MCF-7
cells (cultured in drug free condition) and doxorubicin-
resistant MCF-7 cells (still have nuclear expression of YB-
1) did not generate fused cells in the same culture condi-
tion.
Heterogeneity of MCF-7 cell populations after acquiring 
the drug resistance
The appearance of polyploidy cells may be caused by cell-
to-cell fusion, we employed flow cytometry to test this
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Page 5 of 10assumption and to quantify the cell fusion event occur-
ring after drug treatment. Each MCF-7 subtype, labeled
with either EGFP/YB-1 or DsRed/YB-1, were co-cultured
as a single monolayer. Figures 3A, B, figure 4A and 4B
show that some of these cells were fused and yielded large
multicellular syncytia after treatment with 10 nM doxo-
rubicin for 6 days. Fractions of MCF-7 cells containing
the multiple nuclei were increased after doxorubicin
treatment (inserted table in Figure 3). The polyploidy
cells having heterokaryons (Figure 4B) were identified
and quantified by FACS sorting (Figures 4D and 4E). In
order to increase cell to cell fusion ratio, 20 nM doxorubi-
cin applied (Figure 4E and figure 5C). Initially, 66% out of
R2 fraction containing fused cells was polyploidy, how-
ever, its ratio was decreased down to 31%, suggesting that
chromosomes were eventually lost or re-arranged (Figure
3C and 3E) while acquiring the doxorubicin resistance
(Table insert, Figure 3). The results demonstrate cell
fusion events, followed by genome re-arrangement. The
origin of cancer-initiating cell (cancer stem cell) remains
elusive and the fusion of genetic and cytoplasmic material
between cells could be important in the development of
the cancer stem cell [26].
Induced expression of cell-fusion associated genes after 
doxorubicin treatment
Based on the results of Sentrix Human-6-V3 Expression
Bead Chips on cell fusion (Additional file 1, Table S1) and
literature review, we analyzed the expression patterns of
the following genes (YB-1, c-Kit, MAPT, GST, GM-
CSF2RA, 15-LOX-1, CypB, LCN2, GRP78, RSK1, COX2,
Figure 2 Doxorubicin-induced cell fusion. Translocation of YB-1-
GFP and YB-1-Ds-Red fusion protein in respond to doxorubicin 
treatment. Confocal images of the two fluorescent tagged YB-1 pro-
teins localized to each of the nuclei of non-fused MCF-7 cells and local-
ized in one nucleus in fused MCF-7 cells. A: Control; MCF-7/YB-1-GFP 
transfectant without doxorubicin treatment. B--F: Demonstrate nucle-
ar translocation of YB-1. C: Western blots of YB-1 protein from the frac-
tionated samples; 1 × 106 cells were lysed using Pierce Nuclear and 
Cytoplasmic Extraction Reagent Kit. 10 μg of each cytosolic extract; CE, 
nuclear extract; NE proteins were analyzed by 10% SDS-PAGE and 
Western blotted using specific antibodies diluted 1:1000 (YB-1) or 
1:10000 (GAPDH). Secondary antibody (anti-mouse) diluted 1:25,000 
was used with chemiluminescent substrate for detection. Cells were 
grown for 6 days before visualized by phase contrast and fluorescence 
microscopy (Axiovert 200, Carl Zeiss). D--F: MCF-7/pcDNA3-EGFP/YB-1 
and MCF-7/pDsRed2-N1/YB-1 cells were mixed (1 to 1 ratio) and co-
cultured with 10 nM doxorubicin and visualized by phase contrast and 
fluorescence microscopy. Green; GFP, Red; dsRed, Left panels; GFP de-
tection. Middle panels; dsRed detection. D and F: Right panels; merged 
(yellow or orange) images represent fused MCF-7 cells.
Figure 3 Schema of cell fusion and chromosomal instability. A: Cy-
tosolic cell fusion of two subtype of cells (homotype or heterotype). B 
and D: Most of cells, at the stage of nuclear cell fusion, revealed no fur-
ther propagation and subsequently vanished. C: Viable progeny cells 
propagated again in culture. Giemsa-stained chromosomes of MCF-7 
cells were examined. D: Abnormal sets of chromosomes as a conse-
quence of cell fusion and (E) the cells containing giant nuclei (poly-
ploid) were died out and the diverse populations were analogously 
converged into doxorubicin resistant clones. Table insert, fusion was 
quantitated by counting the number of cells (%) and nuclei present in 
a microscope field.
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guide dots), using custom made dot blot array containing
14 cDNA spots. In the time course study, GAPDH could
not be acceptable for normalization because it was regu-
lated in doxorubicin resistant MCF-7 cells. In the pre-
chemotherapeutic (doxorubicin sensitive) MCF-7 cells,
total 4 genes (YB-1, c-Kit, MAPT, GST) out of 14 were
differentially expressed at specific time points after doxo-
rubicin-treatment (Figure 5A). The results were further
verified by RT-PCR analysis and the expression patterns
of 4 genes, in time course, were similar with the results of
dot blot array analysis (data not shown). Genes such as
YB-1 and GST revealed transient and inducible kinetics
whose level peaked at 6 h and 4 h, respectively in the dox-
orubicin-sensitive MCF-7 cells. GST was known to
detoxify several chemotherapeutic drugs. Therefore, the
shift of over-expression of GST, from 4 h to 24 h in the
doxorubicin resistant MCF-7 cells (Figure 5B), might be a
result of the counter-apoptotic exertion by resisting to
oxidative stress-mediated cytotoxicity of doxorubicin
[27]. Meanwhile, levels of c-Kit and MAPT were also up-
regulated after doxorubicin treatment but with different
kinetics from that of YB-1 and GST.
Expression analysis of drug resistance-related proteins
To investigate whether and how the pro-survival (c-Kit,
ERK1/2, ERK3, MAPT, MDR1, ABCB5) and pro-apop-
totic genes (FAS and PARP-1) are involved in doxorubi-
Figure 4 Cell to cell fusion occurred after doxorubicin treatment. 
A: MCF-7/pcDNA3-EGFP/YB-1 and MCF-7/pDsRed2-N1/YB-1 cells were 
co-cultured (1 to 1 ratio) without doxorubicin, (B) co-cultured with 10 
nM doxorubicin. Arrow heads indicate fusion events (merged colour of 
green and red). C: Doxorubicin induced YB-1 overexpression; each cell 
lysates from (A and B) were separated by 10% SDS-PAGE, visualized by 
Western blot using YB-1, tubulin specific antibodies and secondary an-
tibody (anti-mouse) with chemiluminescent substrate. D and E: FACS 
isolation of fused cells from the co-cultures, gated first (R1) for their 
size, then the gated merged colored cells (R2) were sorted. GFP fluo-
rescence is plotted on the x-axis (FL1-Log_Height), while red fluores-
cence is plotted on the y-axis (FL2-Log_Height). The cells (gated R1) 
represent for the relatively large size of cell population. Double positive 
cells are gated in R2 region represent hybrids.
Figure 5 Differential expression patterns of YB-1, c-Kit, MAPT and 
GST in time course. MCF-7 cells that incubated with 20 nM doxorubi-
cin for the indicated periods of time revealed different kinetic patterns 
for YB-1 and GST expressions between sensitive and resistant MCF-7 
cells. A: Dot blot array analysis on doxorubicin sensitive MCF-7 cells. B: 
Dot blot array analysis on the doxorubicin resistant MCF-7 cells. A and 
B: The scale on x-axis is not in proportion with time. In the time course 
study, actin was employed as a control for normalization, because 
GAPDH was regulated in doxorubicin resistant MCF-7 cells. C: Effect of 
doxorubicin on the expression of drug resistance related target pro-
teins YB-1, c-Kit, ERK1/2, ERK3, FAS, MAPT, MDR1, ABCB5 and PARP-1 in 
the four subtypes of MCF-7 cells. 1, 2 are MCF-7 and MCF-7/vector-YB-
1 respectively without treatment of doxorubicin. 3, MCF-7/vector-YB-1 
with treatment of doxorubicin for 6 h (not fused cells); 4, MCF-7/vector-
YB-1 with treatment of doxorubicin for 6 h (fused cells, FACS sorted R2); 
5, doxorubicin resistant MCF-7 cell line. Numbers indicate a relative lev-
el of protein expression based on the level of intensity of β-actin after 
normalization.
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Page 7 of 10cin-induced molecular events (Figure 5C), we examined
their expression patterns in each subtype of MCF-7 cells
(MCF-7, MCF-7/YB-1, MCF-7/YB-1 not fused, MCF-7/
YB-1 fused, and doxorubicin resistant MCF-7 cells). Cells
were treated with doxorubicin for 6 h and probed with
antibodies against YB-1, c-Kit, ERK1/2, ERK3, FAS,
MAPT, MDR1, ABCB5 and PARP-1. YB-1, c-Kit and
MDR-1 was noticeably expressed following the drug
treatment. However, the expression of FAS and PARP-1
was not detected in the pre-selected doxorubicin resis-
tant MCF-7 cells even after doxorubicin treatment, sug-
gesting that these cells are resistant to drug-induced
apoptosis. Of note, ABCB5 expression was induced upon
drug treatment in the drug sensitive cells (regardless of
non-fused and fused cells), and ABCB5 expression was
not induced in the drug untreated sensitive MCF-7 cells
and in the pre-selected doxorubicin resistant MCF-7 cells
(Figure 5C). Additional efforts are needed to adequately
address this disparity. A specific role of ABCB5 in cell
fusion, through membrane potential regulation, was
reported [22]. If it is the case that the transcription factor
YB-1 regulates ABCB5, doxorubicin treatment may cor-
relate with cell fusion, however, further study is needed.
Most of the long term cultured drug resistant cells
(fused hybrid, R2), that isolated from the parental MCF-7
cells, were anchorage independent. But some of the
anchorage dependent MCF-7 cells exhibited several
unique morphological appearances (data not shown). The
studies on copy number variation, between non-fused
and fused MCF-7 cells, are underway to further define
the correlations between the increased genomic instabil-
ity (by cell fusion) and drug resistance.
Discussion
Transient neoplastic tumor cells frequently have mass
chromosomal alterations, rather than several dozen
genetic mutations which eventually lead to drug resis-
tance [13]. During the generation of doxorubicin resistant
MCF-7 clones, we observed the presence of multiple
nuclei, in the enlarged cytoplasm of cells. The event of
nucleus redistribution of the multi-nuclear cells is trig-
gered by cell fusion or by mitotic failure [15] that
accounts for the plasticity of adult stem cells in vivo [12].
The cell to cell fusion is a newly recognized phenomenon
thought to contribute to drug resistance potential. How-
ever, molecular mechanisms governing cell fusion are
unknown yet. YB-1 was mostly localized to the nucleus
rather than to the cytoplasm in the doxorubicin treated
doxorubicin-sensitive MCF-7/YB-1 cells. Multi-nucle-
ated cells were generated later through cytosolic cell
fusion or some cells further went through nuclear fusion.
Both control and doxorubicin-resistant MCF-7 cells did
not noticeably generate fused cells when cultured in drug
free condition, suggesting MCF-7 cells with doxorubicin-
resistant potential are initiated from the drug induced cell
fusion.
YB-1 is frequently expressed in breast cancers [28,29].
When YB-1 is overexpressed in the mammary gland of
transgenic mice, breast tumors develop in all of mice [15].
In the initial diagnosis, breast cancers were known to
consist of multiple subpopulations of cells with the char-
acteristics of chromosome aberrations [30]. Up to now,
there has been no clear explanation on how this diversity
comes out and how it is re-arranged in breast cancers.
Multi-nucleated cells were generated in doxorubicin
treated MCF-7/YB-1 cells (doxorubicin sensitive). When
two cells were fused, daughter cells inherited characteris-
tics of heterokaryons or of synkaryons. The heterokary-
otic nuclear fusion (0.11%) of two MCF-7 subtypes was
identified and quantified by flow cytometry. Figure 4C
demonstrates a critical role for YB-1 in MCF-7 cell
fusion. Among the doxorubicin treated drug sensitive
MCF-7 cells, fused cells (syncytia) have multiple nuclei
within a large cytoplasm, and 66% among FACS sorted R2
cells were mainly polyploidy. Some chromosomes were
eventually lost or re-arranged in these polyploidy MCF-7
cells, which resulted in the development of doxorubicin
resistance. Therefore, drug-resistance might be a severe
secondary disease occurring after a series of alterations in
chromosome structure and number [9]. Over a century
ago, aneuploidy was found in human cancers describing
that the abnormal chromosome number is a cause of can-
cer rather than an end result [31].
Chromosome instability is believed to be responsible
for the genome-wide changes of transient stages between
early tumorigenesis and subsequent occurrence of
aggressive tumor phenotypes [32,33]. Among these small
subpopulations of MCF-7 cells, a few cells became resis-
tant to doxorubicin, after an initial response (acquired
resistance). However, the reason that some tumor cells
are inherently resistant (intrinsic resistance) without pre-
vious drug treatment is not known yet. If anti-cancer
drug resistant cells represent marginal populations, the
present chemotherapeutic treatment should be concen-
trated on this minor cell population rather than the
impending large population of non-drug resistant cells.
Further more, spontaneously occurring cell fusion with-
out doxorubicin treatment may suggest a correlation with
intrinsic drug resistance.
The overexpression of P-Glycoprotein was closely asso-
ciated with multi-drug resistance [34]. Recently, the
amino acid sequence and protein structure of p-Glyco-
protein ABCB5 was reported [22] and the sequence of
ABCB5 is highly homologous (73%) to both of the known
human p-Glycoprotein isoforms ABCB1 (MDR1) and
ABCB4 (MDR3). We were interested in third member of
the human P-Glycoprotein family ABCB5 (MDR3),
because ABCB5 was known to be a determinant of mem-
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defined progenitor subpopulation [22]. Moreover, in the
development of drug resistance, the correlation between
nuclear YB-1 expression and P-Glycoprotein ABCB5 has
never been demonstrated. We sought to further confirm
the role of ABCB5 in the correlation of pro-survival genes
(c-Kit, ERK1/2, ERK3, MAPT and MDR1) with pro-
apoptotic gene products (FAS and PARP-1) in YB-1
mediated stimulation by doxorubicin. There have been
controversial studies describing fused cells were not tum-
origenic [35], until more conclusive data were available
describing that hybrids become tumorigenic if they lose
certain chromosomes [36]. YB-1 and GST revealed differ-
ent kinetic patterns on doxorubicin sensitive MCF-7
from those on doxorubicin-resistant MCF-7 cells. On
doxorubicin treatment, each peak of the expression levels
of YB-1 and GST were shifted to 2 h and 24 h, respec-
tively in the doxorubicin-resistant MCF-7 cells. The turn
of YB-1 into earlier response was correlated with nuclear
localization of YB-1 that regulates the expression of anti-
apoptotic genes. Moreover, the shift of GST expression
from 4 h to 24 h was associated with reduced apoptosis,
and that may due to detoxification by GST [18]. In this
context, survival functions seemed strengthened by the
suppressed expression of pro-apoptotic FAS and PARP-1
proteins in doxorubicin resistant MCF-7 clones. Upon
drug treatment, YB-1, c-Kit, and MDR1 were all up-regu-
lated compared to doxorubicin non-treated cells. Akt
activation was suggested to regulate the nuclear translo-
cation of transcription factor YB-1, affecting the expres-
sion of MDR1. A novel finding of our study is the
demonstration that c-Kit is co-expressed with ERK3
among drug resistant MCF-7 subpopulations. On the
other hand, P-Glycoprotein ABCB5 was highly expressed
only in the fused MCF-7 cells (R2) while preferentially
suppressed in the doxorubicin resistant cells. However,
further experiments are necessary to confirm whether
ABCB5 is mediated by the expression of YB-1. Ectopi-
cally expressed ABCB5 are known to mediate the hyper-
polarization of the membrane potential [37]. Other stud-
ies illustrated depolarizing the cell line P388 increased
the doxorubicin uptake in the sensitive cells but not in the
resistant cells [38]. More recently, the association
between hyperpolarization of membrane and cell fusion
was demonstrated [39]. Taken as a whole, ABCB5 may
not directly potentiate doxorubicin resistance, but
responsible for increasing heterogeneity in the cancer cell
population. In the doxorubicin resistant cells, the inten-
sity of ERK3 band was 2.6-fold increased than that of
fused cells. Despite the fact that ERK3 is about 50% iden-
tical to ERK1 and ERK2 in its catalytic core [40], key
properties of ERK3 is different from the two classical
MAPKs. Like YB-1, ERK3 also translocates to the
nucleus, upon phosphorylation by MEKs, then ERK3 is
constitutively localized to the nucleus [41]. In contrast to
ERK1 and ERK 2, the regulation of ERK3 expression is
independent of the p53, Bcl-2 and caspase 3, but depen-
dent of p38 pathway activation [40]. Furthermore, the
ERK-3 is known to be susceptible to synthetic antago-
nists.
Our results of current study indicate only a small sub-
population of fused cells obtain acquired resistance, sub-
sequently became stable cell lines having viability against
doxorubicin. Therefore, alterations of epigenetic regula-
tion could be another factor that contributes to tumor
cell diversity [42].
Through cell fusion, a genome causing drug resistance
possibly gets a chance of cellular reprogramming to hide
from chemotherapy and re-emerge as a new type of drug
resistant cancer after the first targeted cancer cells were
eliminated by the therapy. As suggested by other study,
the recurred cancers are new hybrid species which might
have evolved from their parental cells [43]. The doxorubi-
cin resistant-fused hybrid cells were mostly anchorage-
independent and a rare population of the anchorage-
dependent MCF-7 cells exhibited differentiated-progeni-
tor cell-like behavior, suggesting that acquired doxorubi-
cin resistant cells may be originated from the fused cells,
but additional studies should address this possibility. Due
to the complexity of its randomness of acquisition or loss
of genetic traits, we can not explain yet how the fate or
plasticity of cancer cells is exactly affected by the cell
fusion procedure.
Conclusion
During the generation of doxorubicin resistant MCF-7
clones, multiple nuclei were detected in MCF-7 cells.
Exogenously expressed YB-1 was mostly localized to the
nucleus rather than to the cytoplasm in the doxorubicin
treated doxorubicin-sensitive MCF-7/YB-1 cells. We
confirmed the multi-nuclear cells were originated from
cell fusion that accompanied by regulation of YB-1, GST,
ABCB5 and ERK3. Unlike in ovarian cancer, breast can-
cer is composed of more diversified subpopulation of
cells suggesting stem cell like cells may exist. Cell fusion
increased diversity within the MCF-7 cell population and
some of the fused cells exhibited progenitor cell like char-
acteristics. Drug resistance could not be explained only
by reductions of drug accumulation. The present study
shows a correlation between doxorubicin induced tran-
scription factor YB-1 and the transiently regulated fuso-
genic factor ABCB5 [22], suggesting cell fusion and clonal
selection may involve as an additional mechanism in the
progress of acquired drug resistance in MCF-7 cells. By
understanding the mechanism of drug resistance and dis-
covering novel targets for pharmacological, molecular,
and genetic intervention, it may become possible to
increase the usefulness of existing anti-cancer drugs.
Yang et al. BMC Cancer 2010, 10:388
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